				\Box				Complete if Kr	2.Vn		
Substitute for form 1449/PTO			Complete if Known								
(Revised 04/2003)					Application Number Filing Date		er	Concurrently Herewith			
				_	irst Named In	nver	tor	Moon et al.			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			$\overline{}$	iroup Art Uni		loi	Nicon C. a				
				-							
	(Use as r	many sheets as necessary		_	Examiner Name						
Sheet	1	l of	1	LA	ttorney Dock	<u>ket N</u>	lumber	038779/27150	9		
-											
	т			<u>S.</u>	PATENT D	<u>OCI</u>	<u>JMENT</u>	<u>'S</u>			
Examiner	Examiner Cite Document Number		Publication Date			Name of Patentee or			Pages, Columns, Lines, Where		
Initials*	No.	Number - Kind Code	(if known)		M-DD-YYYY			of Cited Document		Relevant Passages of Relevant Figures Appear	
		US-				<u> </u>			\perp		
	ļ	US-				<u> </u>					
	ļ!	US-				 			4		
	<u> </u>	US-				<u> </u>			4		
	ļ!	US-				igspace			1		
		US-							4		
		US-				<u> </u>		 	4		
	<u> </u>	US-				ļ <u></u>			4		
		US-				<u> </u>		<u> </u>	4		
		US-				<u> </u>		- 7	_		
	!	US-		_							
			FORI	FIC	SN PATENT		CUME	NTC	-		
	Г	Foreign Paten		210	MI I MIDITA	<u></u>		NIS	Page	es, Columns, Lines,	English
Examiner Initials	Cite No.	Country Code - Number Kind Code (if known)		Publication Date MM-DD-YYYY			1	f Patentee or nt of Cited ent	Pas	Where Relevant ssages or Relevant Figures Appear	Language Translation Attached
32	- 1	1 EP 0 248 167 A2		12/09/1987		1	Green Corpor				
32	2	EP 0 244 924 B1			01/28/1987	<u>/</u>	Merck	& Co., Inc.			
32	3 EP 0 154 902 A2		09/18/1985		,	New York Blood Center, Inc.					
	<u> </u>								ļ		,
					<u> </u>				<u> </u>		
	l				l						
Examiner Signature		Borr		 		_	Date Consid	lered	/.	2/27/0	y

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.CLT01/4620559v1

		OIA	12.				
Substitute for form 144 /PTGU (Revised 04/2003)		TelUH 2 8 2004 S	<u>.</u>	Complete if Kn wn			
	or form 1449/PT		S.	Application Number	10/720,662		
		4	Filing Date	November 24, 2003			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			(S)	First Named Inventor	Moon et al.		
INFO	KMA110	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	SURE	Group Art Unit	1648		
STAT	rement :	BY APPLI	CANT				
	(Use as many sh	ieets as necessar	y)	Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	038779/271509		

Sheet		OI / Attorney Docket Number 0387/9/2/1309						
		OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached					
32	4	GUIDOTTI ET AL, Viral Clearance Without Destruction of Infected Cells during Acute HBV Infection, Science 1999 284: 825 - 829						
3~	5	ITOH ET AL, A Synthetic Peptide Vaccine Involving the Product of the Pre-S(2) Region of Hepatitis B Virus DNA: Productive Efficacy in Chimpanzees, 1986 Proc. Natl. Acad. Sci USA 83: 9174-9178						
32	6	JONES ET AL, T-cell and Antibody Response Characterization of a New Recombinant pre-S1, pre-S2 and SHBs Antigen-Containing Hepatitis B Vaccine; Demonstration of Superior Anti-SHBs Antibody Induction in Responder Mice, 1999 Vaccine 17: 2528 - 2537						
32	7	KLINKERT ET AL, Pre-S1 Antigens and Antibodies Early in the Course of Acute Hepatitis B Virus Infection, 1986 J. Virol. 58: 522-525						
32	8	MCALEER ET AL, Human Hepatitis B Vaccine from Recombinant Yeast, Nature 1984 307: 178-180						
32	9	MICHEL ET AL, Immunotherapy of Chronic Hepatitis B by Anti HBV Vaccine: From Present to Future, 2001 Vaccine 19: 2395-2399						
32	10	MILICH ET AL, Enhanced Immunogenicity of the Pre-S Region of Hepatitis B Surface Antigen, Science 1985 228: 1195 - 1199						
32	11	MILICH ET AL, Immune Response to the Pre-S(1) Region of the Hepatitis B Surface Antigen (HbsAG): A Pre-S(1)-Specific T Cell Response Can Bypass Nonresponsiveness to the Pre-S(2) and S Regions of HbsAg, 1986 J. Immunol 137: 315-322						
3/2	12	PRIDE ET AL, Evaluation of B and T-Cell Responses in Chimpanzees Immunized with Hepagene, a Hepatitis B Vaccine Containing Pre-S1, Pre-S2 and S Gene Products, 1998 Vaccine 16: 543-550						
32	13	SEEGER ET AL, Hepatitis B Virus Biology, Microbiology and Molecular Biology Reviews 2000 64: 51-68						
		·						

Examiner Signature Sum Z	Date Considered	12/27/04
--------------------------	--------------------	----------

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.